Retevmo Uses

Retevmo (Selpercatinib) is a kinase inhibitor used for the treatment of:

  • Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
  • Adult and pediatric patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
  • Adult and pediatric patients aged 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Side Effects: The most commonly reported retevmo side effects (≥ 25%) include:

  • Decreased calcium
  • Dry mouth
  • Diarrhea
  • Increased creatinine
  • Hypertension
  • Fatigue
  • Edema
  • Decreased
  • Platelets
  • Increased total cholesterol
  • Rash
  • Decreased sodium
  • Constipation
  • Increased alkaline phosphatase

Warnings and Precautions:

  • Monitor ALT and AST prior to initiating retevmo 80 mg capsule, every 2 weeks during the first 3 months, then monthly thereafter.
  • Optimize blood pressure prior to initiating therapy with retevmo 40 mg. Monitor blood pressure after 7 days, at least monthly thereafter.
  • Assess patients who are at significantly higher risk of developing QTc prolongation, including those with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure.
  • Do not administer selpercatinib capsules for at least 2 weeks following major surgery and until adequate wound healing.
  • On behalf of findings from animal reproduction studies and its mechanism of action, retevmo capsules can cause fetal harm if administered to a pregnant woman.
  • Respective women should not breastfeed during treatment with retevmo dosage and for 1 week following the final dose.